Sign in
SLN Stock Price, Chart, Stats & News
Silence Therapeutics PLC
Save
Silence Therapeutics PLC (SLN) does not currently pay a dividend.
512.49M
Market cap
–
Current P/E
–
Forward P/E
SLN chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 61.54% |
Operating margin | -15738.23% |
Pretax margin | -15849.91% |
Net margin | -15851.88% |
Effective tax rate | -0.01% |
ROA | -90.84% |
ROE | -348.47% |
D/E | -0.00x |
Interest coverage ratio | – |
SLN valuation
P/E | – |
P/S | 416.57x |
P/B | 5.04x |
P/CF | -3.74x |
P/FCF | -3.73x |
P/OCF | -3.74x |
PEG | 0.09x |
EV multiple | -3.02x |
About
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver.
Similar securities
Based on sector and market capitalization
Report issue